4th Quarter - Report — HASHEMI STRATEGIC ADVISORS for ULTRAGENYX (2023)

Firm

HASHEMI STRATEGIC ADVISORS

Client

ULTRAGENYX

Income

$39,000

Expenses

—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Precision Medicine Answers for Kids Today Act HELP Co-Pays Act - H.R. 830/S.1375 Newborn screening reauthorization Medicaid Drug Rebate Program (MDRP) rule Inflation Reduction Act - Orphan Drugs Rare Diseases, Ultrarare Diseases and other issues

Lobbyist	Covered position, as disclosed
COOKAB HASHEMI	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 830 (118th), S. 1375 (118th)

Medicare/Medicaid MMM

Medicaid Drug Rebate Program (MDRP) rule

Lobbyist	Covered position, as disclosed
COOKAB HASHEMI	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.